Solu Therapeutics

Overview

Solu Therapeutics is a clinical-stage biotechnology company based in Boston, founded in 2023. The company focuses on developing innovative therapeutics aimed at eliminating disease-driving cells in cancer, immunology, and autoimmunity. It operates with proprietary platforms, including CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera), which enable the targeting of challenging cell surface proteins.

The lead clinical candidate, STX-0712, targets CCR2, a receptor involved in cancer progression, and is currently in Phase 1 clinical trials. Additional programs in development include a novel mast cell depletor for immunological diseases. The company has raised significant funding, including a $41 million Series A round, and actively seeks collaborations to enhance its development efforts. The leadership team comprises experienced professionals in biotechnology and drug development.

Basic Information

Industry	research
Revenue	1.1M
Headquarters	Boston, Massachusetts, United States

Contact Details

Phone: +1 781-874-1100
Website: solutherapeutics.com
LinkedIn: linkedin.com/company/solu-therapeutics

Key Focus Areas & Initiatives

Biotechnology research
Preclinical development
Effector antibody engineering
Deep receptor pockets
CyTAC molecules
Oncology therapeutics
Deep pocket access
Cell surface targets
Targeted immune modulation
GPCR targeting
Unmet medical needs
Immuno-oncology
Long-acting small molecule drugs
Long-acting antagonists
Biotechnology
Pain management
Pharmacokinetics optimization
Cell surface protein targeting
Long-acting therapeutics
TicTAC platform
Clinical-stage biotech
Ion channel targeting
Drug development platform
Molecular linker technology
Immunological cell subsets
CyTAC platform
Efficacy enhancement
Autoimmune disease targets
Small molecule linkers
Immunology
Selective tumor antigen targeting
Oncology
Therapeutic index
Ion channels
TicTAC molecules
Bifunctional small molecules
Efficacy and safety
Antibody-drug conjugates
Antibody-intractable targets
Effector antibodies
Drug target access
Immunology and inflammation
Target validation
Targeted cell killing
Bispecific antibodies
IND-enabling studies
Proprietary linker technology
Bifunctional drugs
Effector antibody conjugation
Long-acting small molecules
Pharmaceuticals
Cytotoxicity targeting
Selective immune cell depletion
Target intractable proteins
GPCRs
Antibody therapeutics
Drug discovery platform
Pathogenic immune cell depletion
B2B
Research and development in the physical, engineering, and life sciences
Hospital & health care
Medical

Technologies Used

Amazon AWS
Google Font API
Google Tag Manager
Hotjar
Microsoft Office 365
Mobile Friendly
Nginx
Outlook
Remote
Typekit
WordPress.org

Affiliated Organizations & Regional Branches